Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IRESS LIMITED Director's Dealing 2021

Sep 2, 2021

65141_rns_2021-09-02_e9ba2caa-44bd-428d-93ba-4d8f62109ca0.pdf

Director's Dealing

Open in viewer

Opens in your device viewer

==> picture [82 x 63] intentionally omitted <==

The Manager Company Announcements Office Australian Stock Exchange Exchange Centre 20 Bridge Street SYDNEY NSW 2000

3 September 2021

Dear Sir or Madam

RE: APPENDIX 3Y – ANDREW WALSH – CEO & MANAGING DIRECTOR

Please find attached an Appendix 3Y announcement relating to the vesting of 67,768 performance rights awarded in 2017 to Andrew Walsh, CEO & Managing Director.

Yours sincerely

==> picture [155 x 67] intentionally omitted <==

Peter Ferguson

Chief Legal Officer & Company Secretary

Iress Limited Corporate Office: Level 16, 385 Bourke Street MELBOURNE VIC 3000 Australia ABN: 47 060 313 359

T +61 3 9018 5800 [email protected]

www.iress.com

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity
Iress Limited
ABN
47 060 313 359

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director Andrew Walsh Date of last notice 24 May 2021

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest Direct
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to
the relevant interest.
Date of change 31 August 2021
No. of securities held prior to change Ordinary Shares
Direct:
408,687
Indirect:
136,791
545,478
Unvested Share/Rights Grants Overview:
Deferred Share Rights
all Series:
42,736
Performance Rights
pre-2019 Series:
200,688
Unvested Rights/Grants under revised 2019 executive
remuneration framework:
  • See chapter 19 for defined terms.

15/07/2020 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

==> picture [252 x 632] intentionally omitted <==

----- Start of picture text -----

||||
|---|---|---|
|Equity Rights:|173,463|
|Performance Rights:|263,799|
|Unvested Share/Rights Grants Details|:|
|2017 Series|
|Performance Rights 2017:|
|●|4 year term, 3 year measurement period commencing 1|
|Jan 2018: -|54,739|
|●|4 year term, 4 year measurement period commencing 1|
|Jan 2017: -|54,739|
|2018 Series|
|Performance Rights 2018:|
|●|4 year term, granted 10 May 2018, 3 year measurement|
|period commencing 1 Jan 2019: -|45,605|
|●|4 year term, granted 10 May 2018, 4 year measurement|
|period commencing 1 Jan 2018: -|45,605|
|2019 Series|
|Deferred Shares Rights 2019:|
|●|3 year term, granted 9 May 2019: -|42,736|
|2019 Series – New Framework|
|Performance Rights 2019:|
|●|3 year term, granted 9 May 2019: –|80,020|
|2020 Series – New Framework|
|Equity Rights 2020:|
|●|2 year term, granted 21 May 2020, 2 year measurement|
|period commencing 28 Feb 2020 – 28 Feb 2022, (shares|
|provided on exercise of any vested Equity Rights are|
|subject to a mandatory 2 year holding lock (28 Feb 2022 –|
|28 Feb 2024): –|76,374|
|Performance Rights 2020:|
|●|3 year term, granted 21 May 2020, 3 year measurement|
|period commencing 1 Jan 2020 – 31 Dec 2022: –|80,916|
|2021 Series - New Framework|
|Equity Rights 2021:|
|●|2 year term, granted in May 2021, 2 year measurement|
|period commencing 28 Feb 2021 - 28 Feb 2023.|
|Shares provided on exercise of any vested Equity Rights|
|are subject to a mandatory 2 year holding lock (28 Feb|
|2023 - 28 Feb 2025) -|97,089|
|Performance Rights 2021:|
|●|3 year term, granted in May 2021, 3 year measurement|
|period commencing 1 Jan 2021 - 31 Dec 2024: -|102,863|

----- End of picture text -----

  • See chapter 19 for defined terms.

15/07/2020 Appendix 3Y Page 2

Appendix 3Y Change of Director’s Interest Notice

Class Ordinary
Number acquired Ordinary Shares
Direct:
67,768
Indirect: Nil
Number disposed Nil
Value/Consideration
Note: If consideration is non-cash, provide details and
estimated valuation
Average price per share $14.87
No. of securities held after change Ordinary Shares
Direct:
476,455
Indirect:
136,791
613,246
Unvested Share/Rights Grants Overview:
Deferred Share Rights
all Series:
42,736
Performance Rights
pre-2019 Series:
91,210
Unvested Rights/Grants under revised 2019 executive
remuneration framework:
Equity Rights:
173,463
Performance Rights:
263,799
Unvested Share/Rights Grants Details:
2018 Series
Performance Rights 2018:
● 4 year term, granted 10 May 2018, 3 year measurement
period commencing 1 Jan 2019: -45,605
● 4 year term, granted 10 May 2018, 4 year measurement
period commencing 1 Jan 2018: -45,605
2019 Series
Deferred Shares Rights 2019:
● 3 year term, granted 9 May 2019: -42,736
2019 Series– New Framework
Performance Rights 2019:
● 3 year term, granted 9 May 2019: –80,020
2020 Series– New Framework
EquityRights 2020:
  • See chapter 19 for defined terms.

15/07/2020 Appendix 3Y Page 3

Appendix 3Y Change of Director’s Interest Notice

● 2 year term, granted 21 May 2020, 2 year measurement
period commencing 28 Feb 2020 – 28 Feb 2022, (shares
provided on exercise of any vested Equity Rights are
subject to a mandatory 2 year holding lock (28 Feb 2022 –
28 Feb 2024): –76,374
Performance Rights 2020:
● 3 year term, granted 21 May 2020, 3 year measurement
period commencing 1 Jan 2020 – 31 Dec 2022: –80,916
2021 Series- New Framework
Equity Rights 2021:
● 2 year term, granted in May 2021, 2 year measurement
period commencing 28 Feb 2021 - 28 Feb 2023.
Shares provided on exercise of any vested Equity Rights
are subject to a mandatory 2 year holding lock (28 Feb
2023 - 28 Feb 2025) -97,089
Performance Rights 2021:
● 3 year term, granted in May 2021, 3 year measurement
period commencing 1 Jan 2021 - 31 Dec 2024: -102,863
Nature of change
Example: on-market trade, off-market trade, exercise of
options, issue of securities under dividend reinvestment
plan, participation in buy-back
Partial vesting and partial lapsing of 2017 Performance Rights
after retest.
● 4.5 year measurement period commencing 1 Jan 2017: -
29,560 vested and 25,179 lapsed.
● 3.5 year measurement period commencing 1 Jan 2018: -
38,208 vested and 16,531 lapsed.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract N/A
Nature of interest N/A
Name
of
registered
holder
(if issued securities)
N/A
Date of change N/A
No. and class of securities to which
interest related prior to change
Note: Details are only required for a contract in relation
to which the interest has changed
N/A
  • See chapter 19 for defined terms.

15/07/2020 Appendix 3Y Page 4

Appendix 3Y Change of Director’s Interest Notice

Interest acquired N/A
Interest disposed N/A
Value/Consideration
Note: If consideration is non-cash, provide details and an
estimated valuation
N/A
Interest after change N/A

Part 3 –[+] Closed period

art 3 –+Closed period
Were the interests in the securities or
contracts detailed above traded during
a +closed period where prior written
clearance was required?
No
If so, was prior written clearance
provided to allow the trade to proceed
during this period?
N/A
If
prior
written
clearance
was
provided, on what date was this
provided?
N/A
  • See chapter 19 for defined terms.

15/07/2020 Appendix 3Y Page 5